StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.02 (+0.05%)

Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Pacira BioSciences's operating income for the twelve months ending Jun 30, 2026 was $19.87M. For fiscal 2025 it was $19.19M. Over ten years it grew 7.3% a year on average. The highest annual figure on record is $89.92M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.19M–
FY2024Dec 31, 2024-$73.37M-183.7%
FY2023Dec 31, 2023$87.68M+46.1%
FY2022Dec 31, 2022$60.02M-33.3%
FY2021Dec 31, 2021$89.92M+94.0%
FY2020Dec 31, 2020$46.35M+342.3%
FY2019Dec 31, 2019$10.48M-34.2%
FY2018Dec 31, 2018$15.92M–
FY2017Dec 31, 2017-$24.94M–
FY2016Dec 31, 2016-$32.02M-438.7%
FY2015Dec 31, 2015$9.46M–
FY2014Dec 31, 2014-$5.17M–
FY2013Dec 31, 2013-$53.29M–
FY2012Dec 31, 2012-$49.30M–
FY2011Dec 31, 2011-$39.10M–
FY2010Dec 31, 2010-$22.71M–
FY2009Dec 31, 2009-$28.55M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.27M-49.8%
Q1 FY2026Mar 31, 2026$6.90M+246.8%
Q4 FY2025Dec 31, 2025$2.34M-90.5%
Q3 FY2025Sep 30, 2025$6.36M–
Q2 FY2025Jun 30, 2025$8.50M-69.9%
Q1 FY2025Mar 31, 2025$1.99M-84.9%
Q4 FY2024Dec 31, 2024$24.70M-25.5%
Q3 FY2024Sep 30, 2024-$139.53M-887.4%
Q2 FY2024Jun 30, 2024$28.24M-29.2%
Q1 FY2024Mar 31, 2024$13.21M–
Q4 FY2023Dec 31, 2023$33.17M–
Q3 FY2023Sep 30, 2023$17.72M-16.8%
Q2 FY2023Jun 30, 2023$39.88M+27.7%
Q1 FY2023Mar 31, 2023-$3.09M-117.8%
Q4 FY2022Dec 31, 2022-$9.89M-334.9%
Q3 FY2022Sep 30, 2022$21.29M-32.3%
Q2 FY2022Jun 30, 2022$31.24M-10.4%
Q1 FY2022Mar 31, 2022$17.39M-10.5%
Q4 FY2021Dec 31, 2021$4.21M-77.6%
Q3 FY2021Sep 30, 2021$31.43M+78.4%
Q2 FY2021Jun 30, 2021$34.84M–
Q1 FY2021Mar 31, 2021$19.44M+13.7%
Q4 FY2020Dec 31, 2020$18.78M+995.8%
Q3 FY2020Sep 30, 2020$17.62M+630.2%
Q2 FY2020Jun 30, 2020-$7.15M-235.5%
Q1 FY2020Mar 31, 2020$17.09M+1484.2%
Q4 FY2019Dec 31, 2019$1.71M-86.0%
Q3 FY2019Sep 30, 2019$2.41M-40.4%
Q2 FY2019Jun 30, 2019$5.28M-19.4%
Q1 FY2019Mar 31, 2019$1.08M–
Q4 FY2018Dec 31, 2018$12.26M+44.9%
Q3 FY2018Sep 30, 2018$4.05M–
Q2 FY2018Jun 30, 2018$6.54M–
Q1 FY2018Mar 31, 2018-$6.94M–
Q4 FY2017Dec 31, 2017$8.46M–
Q3 FY2017Sep 30, 2017-$3.57M–
Q2 FY2017Jun 30, 2017-$15.78M–
Q1 FY2017Mar 31, 2017-$14.05M–
Q4 FY2016Dec 31, 2016-$2.46M–
Q3 FY2016Sep 30, 2016-$20.87M–

More Pacira BioSciences figures

See a number that looks wrong?